Summary
66.59 0.03(0.05%)10/04/2024
Conmed Corp. (CNMD)
Conmed Corp. (CNMD)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.03 | -10.93 | -6.62 | -3.30 | -14.50 | -31.46 | -28.81 | 3,297.45 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 66.59 | |
| Open | 68.33 | |
| High | 69.81 | |
| Low | 65.97 | |
| Volume | 399,827 | |
| Change | 0.02 | |
| Change % | 0.03 | |
| Avg Volume (20 Days) | 267,075 | |
| Volume/Avg Volume (20 Days) Ratio | 1.50 | |
| 52 Week Range | 61.05 - 117.27 | |
| Price vs 52 Week High | -43.22% | |
| Price vs 52 Week Low | 9.07% | |
| Range | -2.55 | |
| Gap Up/Down | 0.77 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,278 | |
| EBIDTA | 206,548,000 | |
| PE Ratio | 27.2644 | |
| PEG Ratio | 5.2900 | |
| WallStreet Target Price | 94.86 | |
| Book Value | 27.7570 | |
| Earnings Per Share | 2.6100 | |
| EPS Estimate Current Quarter | 0.7400 | |
| EPS Estimate Next Quarter | 0.9700 | |
| EPS Estimate Current Year | 4.2900 | |
| EPS Estimate Next Year | 5.5000 | |
| Diluted EPS (TTM) | 2.6100 | |
| Revenues | ||
| Profit Marging | 0.0653 | |
| Operating Marging (TTM) | 0.0963 | |
| Return on asset (TTM) | 0.0368 | |
| Return on equity (TTM) | 0.1025 | |
| Revenue TTM | 1,261,549,056 | |
| Revenue per share TTM | 41.0460 | |
| Quarterly Revenue Growth (YOY) | 0.0570 | |
| Quarterly Earnings Growth (YOY) | 9.5670 | |
| Gross Profit (TTM) | 575,745,000 | |
| Dividends | ||
| Dividend Share | 0.8000 | |
| Dividend Yield | 0.0112 | |
| Valuations | ||
| Trailing PE | 27.2644 | |
| Forward PE | 27.0270 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.7528 | |
| Revenue Enterprise Value | 2.6077 | |
| EBITDA Enterprise Value | 16.8641 | |
| Shares | ||
| Shares Outstanding | 30,800,700 | |
| Shares Float | 30,529,392 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.16 | |
| Insider (%) | 0.55 | |
| Institutions (%) | 120.75 | |
10/04 08:00 EST - businesswire.com
CONMED Corporation Announces Preliminary Third Quarter Financial Information
LARGO, Fla.--(BUSINESS WIRE)--As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE: CNMD) announced preliminary financial information for the third quarter of 2024. The Company expects revenue in the range of $315 million to $318 million and adjusted diluted net earnings per share growth in excess of its previously provided guidance of 9% to 11%. CONMED will report full financial results for the third quarter of 2024 after the ma.
CONMED Corporation Announces Preliminary Third Quarter Financial Information
LARGO, Fla.--(BUSINESS WIRE)--As a follow up to the Current Report on Form 8-K issued by the Company on September 30, 2024, CONMED Corporation (NYSE: CNMD) announced preliminary financial information for the third quarter of 2024. The Company expects revenue in the range of $315 million to $318 million and adjusted diluted net earnings per share growth in excess of its previously provided guidance of 9% to 11%. CONMED will report full financial results for the third quarter of 2024 after the ma.
09/26 07:25 EST - zacks.com
New Strong Sell Stocks for September 26th
AMTB, BZH and CNMD have been added to the Zacks Rank #24 (Strong Sell) List on September 26, 2024.
New Strong Sell Stocks for September 26th
AMTB, BZH and CNMD have been added to the Zacks Rank #24 (Strong Sell) List on September 26, 2024.
09/17 07:27 EST - zacks.com
New Strong Sell Stocks for September 17th
BAMXF, BZH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on September 17 2024.
New Strong Sell Stocks for September 17th
BAMXF, BZH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on September 17 2024.
09/12 11:21 EST - globenewswire.com
Carpal Tunnel Release Systems Market Forecast Report 2024-2030, Featuring Profiles of Arthrex, Conmed, Innomed, MicroAire Surgical Instruments, Resurgens Orthopaedics, S2S Surgical and Trice Medical
Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "Carpal Tunnel Release Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Carpal Tunnel Release Systems was estimated at US$604.4 Million in 2023, and is projected to reach US$809.7 Million by 2030, growing at a CAGR of 4.3% from 2023 to 2030. The growth in the carpal tunnel release systems market is driven by several factors, including technological advancements, an increase in the prevalence of conditions requiring such interventions, and heightened patient preference for minimally invasive procedures. The continuous development of new technologies such as enhanced endoscopic equipment and improved surgical techniques contributes significantly to the efficacy and safety of carpal tunnel surgeries, appealing to both surgeons and patients.
Carpal Tunnel Release Systems Market Forecast Report 2024-2030, Featuring Profiles of Arthrex, Conmed, Innomed, MicroAire Surgical Instruments, Resurgens Orthopaedics, S2S Surgical and Trice Medical
Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "Carpal Tunnel Release Systems - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Carpal Tunnel Release Systems was estimated at US$604.4 Million in 2023, and is projected to reach US$809.7 Million by 2030, growing at a CAGR of 4.3% from 2023 to 2030. The growth in the carpal tunnel release systems market is driven by several factors, including technological advancements, an increase in the prevalence of conditions requiring such interventions, and heightened patient preference for minimally invasive procedures. The continuous development of new technologies such as enhanced endoscopic equipment and improved surgical techniques contributes significantly to the efficacy and safety of carpal tunnel surgeries, appealing to both surgeons and patients.
09/11 08:01 EST - zacks.com
New Strong Sell Stocks for September 11th
B, CNMD and CHEOY have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2024.
New Strong Sell Stocks for September 11th
B, CNMD and CHEOY have been added to the Zacks Rank #5 (Strong Sell) List on September 11, 2024.
08/30 12:36 EST - zacks.com
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
Why Is Conmed (CNMD) Up 13.2% Since Last Earnings Report?
Conmed (CNMD) reported earnings 30 days ago. What's next for the stock?
08/19 16:05 EST - businesswire.com
CONMED Corporation to Participate in a Fireside Chat at the Wells Fargo Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Wednesday, September 4, 2024. A live webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.conmed.com and will.
CONMED Corporation to Participate in a Fireside Chat at the Wells Fargo Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference at 8:00 a.m. ET on Wednesday, September 4, 2024. A live webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.conmed.com and will.
08/19 08:30 EST - zacks.com
New Strong Sell Stocks for August 19th
ARRY, BSM and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2024.
New Strong Sell Stocks for August 19th
ARRY, BSM and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2024.
08/15 08:05 EST - zacks.com
New Strong Sell Stocks for August 15th
ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.
New Strong Sell Stocks for August 15th
ARCO, CNMD and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 15, 2024.
08/05 08:45 EST - zacks.com
New Strong Sell Stocks for August 5th
AMX, CNH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2024.
New Strong Sell Stocks for August 5th
AMX, CNH and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on August 5, 2024.
08/01 13:15 EST - zacks.com
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
CONMED (CNMD) Q2 Earnings Beat, Sales Rise Y/Y, '24 View Cut
CONMED (CNMD) beats second-quarter earnings estimates on the back of higher revenues and lower costs and expenses. However, the result reflects the continued impact of supply chain issues.
07/31 22:33 EST - seekingalpha.com
CONMED Corporation (CNMD) Q2 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Curt Hartman – Chair of the Board, President and Chief Executive Officer Todd Garner – Executive Vice President and Chief Financial Officer Pat Beyer – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Robbie Marcus – JPMorgan Dino Weinstock – Wells Fargo Travis Steed – BofA Mike Matson – Needham Kristen Stewart – CL King Operator Good day, and thank you for standing by. Welcome to CONMED's Second Quarter Fiscal 2024 Earnings Conference Call.
CONMED Corporation (CNMD) Q2 2024 Earnings Call Transcript
CONMED Corporation (NYSE:CNMD ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Curt Hartman – Chair of the Board, President and Chief Executive Officer Todd Garner – Executive Vice President and Chief Financial Officer Pat Beyer – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Robbie Marcus – JPMorgan Dino Weinstock – Wells Fargo Travis Steed – BofA Mike Matson – Needham Kristen Stewart – CL King Operator Good day, and thank you for standing by. Welcome to CONMED's Second Quarter Fiscal 2024 Earnings Conference Call.
07/31 21:05 EST - zacks.com
Here's What Key Metrics Tell Us About Conmed (CNMD) Q2 Earnings
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's What Key Metrics Tell Us About Conmed (CNMD) Q2 Earnings
Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
07/31 19:01 EST - zacks.com
Conmed (CNMD) Q2 Earnings Beat Estimates
Conmed (CNMD) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.83 per share a year ago.
Conmed (CNMD) Q2 Earnings Beat Estimates
Conmed (CNMD) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.83 per share a year ago.
07/24 11:07 EST - zacks.com
Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Conmed (CNMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
06/27 10:45 EST - zacks.com
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
Here's Why You Should Retain CONMED (CNMD) Stock for Now
CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
05/23 16:05 EST - businesswire.com
CONMED Corporation to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.conmed.com and will b.
CONMED Corporation to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:00 a.m. ET on Thursday, June 6, 2024. A live webcast of the fireside chat will be accessible through the “Investors” section of the Company's website at www.conmed.com and will b.
05/22 16:05 EST - businesswire.com
CONMED Corporation Announces Quarterly Cash Dividend
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 22, 2024, payable on July 5, 2024, to all shareholders of record as of June 14, 2024. About CONMED Corporation CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties, including orth.
CONMED Corporation Announces Quarterly Cash Dividend
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) announced today that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 22, 2024, payable on July 5, 2024, to all shareholders of record as of June 14, 2024. About CONMED Corporation CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a variety of specialties, including orth.
05/19 14:08 EST - investorplace.com
Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains
Following the so-called “smart money” is often a wise strategy for retail investors. Most individual investors fail to outperform the broader market over the long-run.
Follow the Whales: 3 Genius Stocks the Smart Money Is Piling Into for Triple-Digit Gains
Following the so-called “smart money” is often a wise strategy for retail investors. Most individual investors fail to outperform the broader market over the long-run.
05/01 16:05 EST - businesswire.com
CONMED Corporation to Present at the BofA Securities Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m. ET) on Tuesday, May 14, 2024 in Las Vegas, NV. A live audio webcast of the presentation will be accessible through the “Investors” section of th.
CONMED Corporation to Present at the BofA Securities Healthcare Conference
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that Curt R. Hartman, Chair of the Board, President, and Chief Executive Officer, Todd W. Garner, Executive Vice President and Chief Financial Officer, and Pat Beyer, Chief Operating Officer, will present at the BofA Securities Healthcare Conference at 2:20 p.m. PT (5:20 p.m. ET) on Tuesday, May 14, 2024 in Las Vegas, NV. A live audio webcast of the presentation will be accessible through the “Investors” section of th.